Abstract
The
“hotness”
or
“coldness”
of
the
tumors
are
determined
by
information
cancer
cells
themselves,
tumor
immune
characteristics,
microenvironment,
and
signaling
mechanisms,
which
key
factors
affecting
patients’
clinical
efficacy.
switch
mechanism
its
corresponding
pathological
characteristics
treatment
strategies
frontier
hot
spot
treatment.
How
to
distinguish
effectively
clarify
causes,
microenvironment
state,
very
important
for
response
efficacy
treatments.
Starting
from
concept
cold
tumor,
this
review
systematically
summarized
molecular
influencing
factors,
therapeutic
“hot
tumors,”
analyzed
immunophenotypes,
pathways,
markers
that
contribute
tumors”
in
details.
Different
“cold
based
on
were
with
drug
targets
proteins
tumors.”
Furthermore,
combines
different
traditional
medicine
modern
medicine,
provide
a
basis
guidance
decision‐making
Tertiary
lymphoid
structures
(TLS)
are
ectopic
cellular
aggregates
that
resemble
secondary
organs
in
their
composition
and
structural
organization.
In
contrast
to
organs,
TLS
not
imprinted
during
embryogenesis
but
formed
non-lymphoid
tissues
response
local
inflammation.
exhibiting
a
variable
degree
of
maturation
found
solid
tumors.
They
composed
various
immune
cell
types
including
dendritic
cells
antigen-specific
B
T
lymphocytes,
together,
actively
drive
the
against
tumor
development
progression.
This
review
highlights
successive
steps
leading
formation
its
association
with
clinical
outcomes.
We
discuss
role
played
by
tumor-infiltrating
lymphocytes
plasma
cells,
prognostic
value
tumors
immunotherapeutic
responses
potential
for
future
targeting.
Frontiers in Cell and Developmental Biology,
Год журнала:
2021,
Номер
9
Опубликована: Июнь 7, 2021
The
immune
system
plays
a
crucial
role
in
cancer
development
either
by
fostering
tumor
growth
or
destroying
cells,
which
has
open
new
avenues
for
immunotherapy.
It
was
only
over
the
last
decade
that
of
B
cells
controlling
anti-tumor
responses
milieu
begun
to
be
appreciated.
and
plasma
can
exert
effects
through
antibody-dependent
cell
cytotoxicity
(ADCC)
activation
complement
cascade,
even
though
their
effector
functions
extend
beyond
classical
humoral
immunity.
In
tissues,
found
lymphoid
aggregates,
known
as
tertiary
structures
(TLSs),
well-organized
non-encapsulated
composed
stromal
cells.
These
reflect
process
neogenesis
occurring
peripheral
tissues
upon
long-lasting
exposure
inflammatory
signals.
TLS
provides
an
area
intense
antigen
presentation
lead
optimal
T
functions,
well
generation
further
differentiated
antibody-secreting
memory
Of
clinical
interest,
crosstalk
between
antigen-experienced
exhausted
CD8
+
within
mature
recently
associated
with
improved
response
checkpoint
blockade
(ICB)
melanoma,
sarcoma
lung
cancer.
Otherwise,
sparsely
distributed
microenvironment
organized
immature
TLSs
were
immune-regulatory
inhibiting
immunity
secretion
anti-inflammatory
cytokines.
Such
phenotype
might
arise
when
interact
malignant
rather
than
dendritic
Differences
spatial
distribution
likely
underlie
discrepancies
inferred
from
human
samples
mouse
models.
Many
fast-growing
orthotopic
tumors
develop
cell-rich
bulk
reduced
stroma
are
devoid
TLSs,
highlights
importance
carefully
selecting
pre-clinical
summary,
strategies
promote
formation
close
proximity
favor
immunotherapy
responses.
Here,
cellular
molecular
programs
coordinating
development,
organization
will
reviewed,
focusing
on
translational
relevance
Abstract
The
“hotness”
or
“coldness”
of
the
tumors
are
determined
by
information
cancer
cells
themselves,
tumor
immune
characteristics,
microenvironment,
and
signaling
mechanisms,
which
key
factors
affecting
patients’
clinical
efficacy.
switch
mechanism
its
corresponding
pathological
characteristics
treatment
strategies
frontier
hot
spot
treatment.
How
to
distinguish
effectively
clarify
causes,
microenvironment
state,
very
important
for
response
efficacy
treatments.
Starting
from
concept
cold
tumor,
this
review
systematically
summarized
molecular
influencing
factors,
therapeutic
“hot
tumors,”
analyzed
immunophenotypes,
pathways,
markers
that
contribute
tumors”
in
details.
Different
“cold
based
on
were
with
drug
targets
proteins
tumors.”
Furthermore,
combines
different
traditional
medicine
modern
medicine,
provide
a
basis
guidance
decision‐making